Clinical characteristics and outcomes of elderly patients treated with an implantable cardioverter-defibrillator or cardiac resynchronization therapy in a real-world setting: Data from the Israeli ICD Registry

Suleiman, Mahmoud; Goldenberg, Ilan; Haim, Moti; Schliamser, Jorge E.; Boulos, Monther; Ilan, Michael; Swissa, Moshe; Gavrielov-Yusim, Natalie; Fuchs, Therese; Amit, Guy; Glikson, Michael

doi:10.1016/j.hrthm.2013.12.003

Cited by 27 publications

(25 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent analysis from the National Cardiovascular Disease Registry -Implantable cardio defibrillator (ICD) registry did demonstrate a survival benefit in octogenarians receiving a CRT-defibrillator (CRT-D) versus ICD 13 . This observation of mortality benefit of CRT-D over ICD has been confirmed in the Israeli ICD-registry 14 . However, no patients receiving a CRT-pacemaker (CRT-P) were included in these analyses and the mode of death was not presented.…”

Section: Introductionsupporting

confidence: 55%

Mode of Death in Octogenarians Treated With Cardiac Resynchronization Therapy

Martens

Verbrugge

Nijst

et al. 2016

Journal of Cardiac Failure

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 55%

Mode of Death in Octogenarians Treated With Cardiac Resynchronization Therapy

Martens

Verbrugge

Nijst

et al. 2016

Journal of Cardiac Failure

View full text Add to dashboard Cite

show abstract

“…In our study, older patients who underwent CRT presented more comorbidities than did their younger counterparts. Such differences have been highlighted in other studies [8] and registries [7,15].…”

Section: Discussionmentioning

confidence: 80%

Predictors of clinical outcomes after cardiac resynchronization therapy in patients ≥75 years of age: a retrospective cohort study

Champ‐Rigot

Cornille

Ollitrault

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Cardiac resynchronization therapy has been shown to benefit selected patients with heart failure and reduced ejection fraction. Older patients have been underrepresented in randomized trials. This study was conducted to determine whether predictive factors for cardiac resynchronization therapy outcomes differ in patients older and younger than 75 years of age. Methods: Consecutive patients who received a cardiac resynchronization device cardiac resynchronization therapy between 2013 and 2016 in our center were retrospectively included in this cohort study. The primary endpoint was cardiac resynchronization therapy effectiveness, which was defined as survival for one year with both no heart failure hospitalization and improvement by one or more NYHA class. The secondary endpoints were mortality, complications, and device therapies. Results: Among the 243 patients included, 102 were ≥75 years old. Cardiac resynchronization therapy effectiveness was observed in 70 patients (50%) <75 years old and in 48 patients (47%) ≥75 years old (p=0.69). NYHA class ≥III (OR=6.02; CI95% [1.33-18.77], p=0.002) was a predictive factor for cardiac resynchronization therapy effectiveness only in the ≥75-year-old group, while atrial fibrillation was independently negatively associated with the primary endpoint in the <75-year-old group (OR=0.28; CI95% [0.13-0.62], p=0.001). The one-year mortality rate was 14%, with no difference between age groups. Rescue cardiac resynchronization therapy and atrial fibrillation were independent predictive factors for mortality in both age groups. Eighty-two complications occurred in 45 patients (19%), with no difference between groups. Defibrillator use and QRS duration were independent predictive factors for complications in both age groups. There was no difference between groups considering device therapies. Conclusion: At one year, cardiac resynchronization therapy response is not compromised by patient age. In older patients, highly symptomatic individuals with NYHA class ≥III have better outcomes after cardiac resynchronization therapy. KEYWORDS: Resynchronization therapy; heart failure; aged; treatment outcome

show abstract

“…Our rate of implant-related complications is similar to the one reported by the COMPANION investigators [2], who found these adverse effects in 8 % of their population of younger individuals than ours. Furthermore, recent studies show a similar rate of complications in young and elderly patients [24,27], with a very low rate of significant complications (associated with surgical reinterventions at 1 year <3 % regardless of age [27]). Thus, elderly patients have a low rate of procedure-related complications and this rate is similar to that of young patients.…”

Section: Discussionmentioning

confidence: 80%